Lawmakers in Albany are deciding the future of New York’s intellectual and developmental disability (I/DD) care system. Here’s what’s at stake.

Celldex will present multiple Phase 2 data sets on barzolvolimab for chronic urticarias at AAAAI 2026, supporting its first-in-class profile.